391 related articles for article (PubMed ID: 19185026)
21. Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3?
Alves S; Nascimento-Ferreira I; Dufour N; Hassig R; Auregan G; Nóbrega C; Brouillet E; Hantraye P; Pedroso de Lima MC; Déglon N; de Almeida LP
Hum Mol Genet; 2010 Jun; 19(12):2380-94. PubMed ID: 20308049
[TBL] [Abstract][Full Text] [Related]
22. Machado-Joseph disease/spinocerebellar ataxia type 3.
Paulson H
Handb Clin Neurol; 2012; 103():437-49. PubMed ID: 21827905
[TBL] [Abstract][Full Text] [Related]
23. Potassium channel dysfunction and depolarized resting membrane potential in a cell model of SCA3.
Jeub M; Herbst M; Spauschus A; Fleischer H; Klockgether T; Wuellner U; Evert BO
Exp Neurol; 2006 Sep; 201(1):182-92. PubMed ID: 16765348
[TBL] [Abstract][Full Text] [Related]
24. [Recent advances in molecular genetics of spinocerebellar ataxia type 3/Machado-Joseph disease].
Jia D; Jiang H; Tang B
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):660-2. PubMed ID: 19065526
[TBL] [Abstract][Full Text] [Related]
25. Identification and functional dissection of localization signals within ataxin-3.
Antony PM; Mäntele S; Mollenkopf P; Boy J; Kehlenbach RH; Riess O; Schmidt T
Neurobiol Dis; 2009 Nov; 36(2):280-92. PubMed ID: 19660550
[TBL] [Abstract][Full Text] [Related]
26. Gene expression profiling in ataxin-3 expressing cell lines reveals distinct effects of normal and mutant ataxin-3.
Evert BO; Vogt IR; Vieira-Saecker AM; Ozimek L; de Vos RA; Brunt ER; Klockgether T; Wüllner U
J Neuropathol Exp Neurol; 2003 Oct; 62(10):1006-18. PubMed ID: 14575237
[TBL] [Abstract][Full Text] [Related]
27. Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease.
Matos CA; de Macedo-Ribeiro S; Carvalho AL
Prog Neurobiol; 2011 Sep; 95(1):26-48. PubMed ID: 21740957
[TBL] [Abstract][Full Text] [Related]
28. Six cases of SCA3/MJD patients that mimic hereditary spastic paraplegia in clinic.
Wang YG; Du J; Wang JL; Chen J; Chen C; Luo YY; Xiao ZQ; Jiang H; Yan XX; Xia K; Pan Q; Tang BS; Shen L
J Neurol Sci; 2009 Oct; 285(1-2):121-4. PubMed ID: 19608203
[TBL] [Abstract][Full Text] [Related]
29. [Clinical features and gene mutation analysis in Machado-Joseph disease of spinocerebellar ataxia type 3 in littoral of Zhejiang].
Jin YY; Zeng AP; Cai HB; Wu F; Feng Z; Hong Q; Zhang L; Jiang ZK
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Apr; 23(2):132-4. PubMed ID: 20104758
[TBL] [Abstract][Full Text] [Related]
30. Caffeine and adenosine A(2A) receptor inactivation decrease striatal neuropathology in a lentiviral-based model of Machado-Joseph disease.
Gonçalves N; Simões AT; Cunha RA; de Almeida LP
Ann Neurol; 2013 May; 73(5):655-66. PubMed ID: 23625556
[TBL] [Abstract][Full Text] [Related]
31. Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3).
Hübener J; Weber JJ; Richter C; Honold L; Weiss A; Murad F; Breuer P; Wüllner U; Bellstedt P; Paquet-Durand F; Takano J; Saido TC; Riess O; Nguyen HP
Hum Mol Genet; 2013 Feb; 22(3):508-18. PubMed ID: 23100324
[TBL] [Abstract][Full Text] [Related]
32. Altered glucose metabolism and its association with carbonic anhydrase 8 in Machado-Joseph Disease.
Lin GY; Ma CY; Kuo LC; Hsieh BY; Wang H; Liu CS; Hsieh M
Metab Brain Dis; 2022 Aug; 37(6):2103-2120. PubMed ID: 35488942
[TBL] [Abstract][Full Text] [Related]
33. Machado-Joseph Disease: A Stress Combating Deubiquitylating Enzyme Changing Sides.
Dantuma NP; Herzog LK
Adv Exp Med Biol; 2020; 1233():237-260. PubMed ID: 32274760
[TBL] [Abstract][Full Text] [Related]
34. Prenatal diagnosis of Machado-Joseph disease/Spinocerebellar Ataxia Type 3 in Taiwan: early detection of expanded ataxin-3.
Tsai HF; Liu CS; Chen GD; Lin ML; Li C; Chen YY; Wang BT; Hsieh M
J Clin Lab Anal; 2003; 17(5):195-200. PubMed ID: 12938149
[TBL] [Abstract][Full Text] [Related]
35. A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration.
Goti D; Katzen SM; Mez J; Kurtis N; Kiluk J; Ben-Haïem L; Jenkins NA; Copeland NG; Kakizuka A; Sharp AH; Ross CA; Mouton PR; Colomer V
J Neurosci; 2004 Nov; 24(45):10266-79. PubMed ID: 15537899
[TBL] [Abstract][Full Text] [Related]
36. Proteotoxic stress increases nuclear localization of ataxin-3.
Reina CP; Zhong X; Pittman RN
Hum Mol Genet; 2010 Jan; 19(2):235-49. PubMed ID: 19843543
[TBL] [Abstract][Full Text] [Related]
37. Toward understanding Machado-Joseph disease.
Costa Mdo C; Paulson HL
Prog Neurobiol; 2012 May; 97(2):239-57. PubMed ID: 22133674
[TBL] [Abstract][Full Text] [Related]
38. Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.
Li X; Liu H; Fischhaber PL; Tang TS
Prog Neurobiol; 2015 Sep; 132():34-58. PubMed ID: 26123252
[TBL] [Abstract][Full Text] [Related]
39. Ataxin-3 is translocated into the nucleus for the formation of intranuclear inclusions in normal and Machado-Joseph disease brains.
Fujigasaki H; Uchihara T; Koyano S; Iwabuchi K; Yagishita S; Makifuchi T; Nakamura A; Ishida K; Toru S; Hirai S; Ishikawa K; Tanabe T; Mizusawa H
Exp Neurol; 2000 Oct; 165(2):248-56. PubMed ID: 10993685
[TBL] [Abstract][Full Text] [Related]
40. Does DNA methylation in the promoter region of the ATXN3 gene modify age at onset in MJD (SCA3) patients?
Emmel VE; Alonso I; Jardim LB; Saraiva-Pereira ML; Sequeiros J
Clin Genet; 2011 Jan; 79(1):100-2. PubMed ID: 21143471
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
